Core Insights - Cronos Group Inc. achieved record net revenue in Q4 2025 and FY 2025, with Q4 revenue increasing by 47% year-over-year to $44.5 million and FY revenue increasing by 25% year-over-year to $146.6 million [1][2][16] - The company reported strong performance driven by consumer demand, expansion at Cronos GrowCo, and contributions from international markets [2][3] - The company maintains a robust balance sheet with $832 million in cash and cash equivalents and short-term investments [1] Financial Performance - Q4 2025 net revenue of $44.5 million increased by $14.2 million from Q4 2024, primarily due to higher cannabis flower sales in Israel and other countries [10] - Gross profit for Q4 2025 was $16.2 million, an increase of $5.4 million from Q4 2024, driven by higher average sales prices and sales volumes [10] - For FY 2025, gross profit reached $62.8 million, up $37.6 million from FY 2024, attributed to lower inventory step-up costs and higher sales prices [16] Brand and Market Position - The Spinach brand maintained a strong position in Canada, ranking 2 overall and 4 in the flower category with a market share of 5.1% [11] - SOURZ by Spinach led the edibles category with a market share of 21.7% in Q4 2025, continuing to innovate with new product launches [12] - PEACE NATURALS consistently ranked as the top cannabis brand in Israel, achieving record sales volume and revenue throughout 2025 [15] International Expansion - The PEACE NATURALS brand expanded into new international markets, including Australia, Malta, and Switzerland, significantly increasing its global footprint [17] - International revenue outside Israel grew by 68% year-over-year in Q4 2025, reflecting strong demand and normalized shipment timing [17] Strategic Acquisition - Cronos Group entered into an agreement to acquire CanAdelaar B.V. for approximately $67 million, which will enhance its strategic footprint in Europe and leverage its borderless product strategy [22][24] - CanAdelaar operates a significant greenhouse facility and has rapidly grown its market share in the Dutch cannabis market, achieving net revenue of $47.3 million in the twelve months ended September 30, 2025 [23] Operational Updates - The company reported a net loss of $0.5 million in Q4 2025, a significant decrease from net income of $43.9 million in Q4 2024, primarily due to foreign currency transaction losses [10] - Adjusted EBITDA for FY 2025 improved by $45.1 million to $10.1 million, driven by higher adjusted gross profit and lower operating expenses [16]

Core Insights - Anterix has expanded its collaboration with Qualcomm to enhance the adoption of next-generation connectivity for utilities and critical infrastructure operators across the nation [1][2] - The partnership aims to provide a comprehensive private wireless connectivity platform that supports safer operations, greater resilience, and long-term grid modernization for the utility sector [2][3] Collaboration Details - The collaboration focuses on developing new industrial-grade IoT chipsets specifically optimized for utility use cases, including Qualcomm's Snapdragon SDX35-3 and SDX32-3 IoT Modems, which will enable 4G and 5G connectivity on Anterix's 900 MHz broadband platform [3][4] - Eight utilities have already chosen Anterix-enabled private wireless as the foundation for their next-generation grid connectivity [3] Strategic Importance - The partnership provides utilities with a scalable roadmap to 5G, delivering immediate operational value while supporting long-term network evolution [4] - The collaboration is positioned to future-proof the adoption of private wireless networks, enhancing operational efficiency and resilience in the energy sector [4]

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before the U.S. financial markets open. Kura’s management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update. The live we ...

COLUMBUS, Ohio, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bread Financial Holdings, Inc. (NYSE: BFH) (“Bread Financial” or the “Company”) today announced that its Board of Directors (the “Board”) has approved a $600 million increase to the Company’s existing share repurchase authorization. As of December 31, 2025, the Company had $240 million remaining on its open share repurchase authorization. The Company made an additional $75 million of repurchases to-date during 2026, meaning that $165 million of share repurch ...

Local Community Support Advances Silver-Dominant Maria Norte Toward Access and Development ExecutionVANCOUVER, British Columbia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rio Silver Inc. (“Rio Silver” or the “Company”) (TSX-V: RYO | OTC: RYOOF) is pleased to announce that it has received permission from the local community to commence planned site activities at its Maria Norte Project in Peru. The agreement allows the Company to begin establishing the necessary infrastructure to efficiently start exploration and de ...

Figure 1 MD Projects-Eeyou Istchee James Bay Figure 2 Caniaspic Au 2025 Results Figure 3 Caniapisc Au Planned IP Figure 4 Samples 2025 Figure 5 Samples 2025 Figure 6 Samples 2025 MONTREAL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce the start of an induced polarization ground (“IP’) geophysical survey on its Caniapisc Au project, in the Eeyou Istchee James Bay and Caniapiscau regions. The Caniapisc Au project is wholly ...

TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the timing of its Premarket Approval (“PMA”) submission to the U.S. Food and Drug Administration (“FDA”) for its hemoadsorption device to treat endotoxic septic shock. Following recent interaction with the FDA, the Company now expects to submit its PMA around the end of April to mid-M ...

JENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Leerink Partners Global Healthcare Conference. Details are as follows: Leerink Partners Global Healthcare ConferenceMarch 8 - 11, 2026 in Miami, FLFireside chat on March 9 at 9:20 AM ET InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view the fireside ch ...

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations w ...

Rare earth element and niobium anomalies found in sediments and surrounding rocksVancouver, British Columbia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Initial prospecting results and geological observations suggest that the broader area encompassing North American Niobium and Critical Minerals Corp.’s (CSE: NIOB) (OTCQB: NIOMF) (FSE: KS82.F) Bardy, Blanchette and Sabot projects in Québec may be comparable in style to the large rare-earth element (REE) deposits found in Greenland. As such, the Company has begun a t ...